Hemorrhoid

Herbal medicinal product: Vitis viniferae foliumArray, C: ongoing call for scientific data

Retrieved on: 
Wednesday, April 3, 2024
Community, Hypersensitivity, Chronic venous insufficiency, Weight, Cramp, Vein, Health, System, Varicose veins, Headache, Patient, Monograph, Committee, Hemorrhoid, Fatigue, Herbal medicine, Date, Allergy, Itch, Commission, Venous insufficiency, Nausea, Agency, Mouth, Skin, Water, Safety, Pain, Stomach, Medicine, Dietary supplement

Herbal medicinal product: Vitis viniferae foliumArray, C: ongoing call for scientific data

Key Points: 


Herbal medicinal product: Vitis viniferae foliumArray, C: ongoing call for scientific data

Oramed Letter to Shareholders

Retrieved on: 
Tuesday, February 20, 2024
Acquisition, Senior, Letter, Joint venture, Investment, Marketing, FDA, Hemorrhoid, Note, Herpes labialis, Wart, JV, BMI, License, Patient, Pruritus ani, Anal, Body mass index, Failure, Glycated hemoglobin, Partnership, Pharmaceutical industry

NEW YORK, Feb. 20, 2024 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) ( www.oramed.com ), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today issued a Letter to Shareholders from its President and Chief Executive Officer, Nadav Kidron.

Key Points: 
  • NEW YORK, Feb. 20, 2024 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) ( www.oramed.com ), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today issued a Letter to Shareholders from its President and Chief Executive Officer, Nadav Kidron.
  • I am pleased to share with you an update regarding Oramed.
  • Oramed and HTIT Joint Venture:
    In January 2024, Oramed entered into a definitive agreement with HTIT, marking a milestone in the creation of a joint venture ("JV"), centered around Oramed's cutting-edge oral drug delivery technology.
  • We thank you for your support and look forward to keeping our shareholders updated on the important milestones ahead.

Herbal medicinal product: Plantaginis ovatae semenArray, C: ongoing call for scientific data

Retrieved on: 
Friday, February 16, 2024
Psyllium, Key, Inhalation, Committee, Monograph, Conjunctivitis, Inflammation, Pain, Bronchospasm, Anaphylaxis, Hemorrhoid, Human, Eye, Allergy, Date, Defecation, Risk, Seed, Mouth, Constipation, Safety, Stomach, Rectum, Plantago, Rhinitis, Patient, Medicine, Bleeding, Abdominal distension, Anal, Herbal medicine, Flatulence, Failure, Water

Herbal medicinal product: Plantaginis ovatae semenArray, C: ongoing call for scientific data

Key Points: 


Herbal medicinal product: Plantaginis ovatae semenArray, C: ongoing call for scientific data

Herbal medicinal product: Plantaginis ovatae seminis tegumentumArray, C: ongoing call for scientific data

Retrieved on: 
Friday, February 16, 2024
Key, Inhalation, Committee, Monograph, Diet, Conjunctivitis, Inflammation, Pain, Bronchospasm, Anaphylaxis, Hemorrhoid, Human, Eye, Allergy, Date, Defecation, Risk, Seed, Mouth, Constipation, Hypercholesterolemia, Safety, Irritable bowel syndrome, Stomach, Rectum, Rhinitis, Abdominal pain, Patient, Medicine, Disease, Bleeding, Abdominal distension, Anal, Herbal medicine, Flatulence, Failure, Water

Herbal medicinal product: Plantaginis ovatae seminis tegumentumArray, C: ongoing call for scientific data

Key Points: 


Herbal medicinal product: Plantaginis ovatae seminis tegumentumArray, C: ongoing call for scientific data

Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2024 Financial Results and Provides Business Update

Retrieved on: 
Wednesday, February 14, 2024
TenX, Shareholder, Catheter, Accounting, Research, FDA, Food, Hemorrhoid, BLA, Calendar, PDUFA, FIRST, G&A, Pharmaceutical industry

CRANFORD, N.J., Feb. 14, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products today reported business and financial results for the fiscal first quarter 2024 ended December 31, 2023.

Key Points: 
  • "We had a strong first quarter of fiscal 2024 during which we achieved multiple mission critical goals.
  • FIRST QUARTER 2024 Financial Results:
    As of December 31, 2023, the Company had $20.3 million in cash and cash equivalents.
  • R&D expenses were $2.6 million for the first quarter ended December 31, 2023, compared to $3.4 million for the first quarter ended December 31, 2022.
  • G&A expenses were $3.7 million for the first quarter ended December 31, 2023, compared to $2.6 million for the first quarter ended December 31, 2022.

Revolutionizing Hemorrhoid Relief: Introducing HemFuse EXT with Aquamin™

Retrieved on: 
Wednesday, January 10, 2024
Inflammation, Hemorrhoid, Safety, Health, Validation, Pain, Pharmaceutical industry

ROSEVILLE, Calif., Jan. 10, 2024 /PRNewswire-PRWeb/ -- Exclusive Pharmaceuticals, a trailblazer in health and wellness solutions, is proud to announce the launch of HemFuse EXT, a groundbreaking patented capsule formula designed to bring unprecedented relief to individuals suffering from hemorrhoids. This innovative product features the incorporation of Aquamin™, a key ingredient known for its natural healing properties, setting a new standard in the field of hemorrhoid relief.

Key Points: 
  • Patented Capsule Formula: HemFuse EXT stands out as a result of its proprietary formula, combining a patented blend of ingredients with the healing power of Aquamin™.
  • Extended Relief: The capsule form of HemFuse EXT allows for extended relief, providing a sustained release of the active ingredients.
  • Convenient and Discreet: The capsule format of HemFuse EXT offers users a convenient and discreet option for managing hemorrhoid symptoms.
  • For more information on HemFuse EXT with Aquamin™, please visit https://exnutrition.com/ or contact Branden, Founder, at [email protected] .

Bloop Anorectal Care Products Now Available on Amazon - Revolutionizing Colorectal Wellness!

Retrieved on: 
Tuesday, December 5, 2023
Cream, Woman, Customs officer, Fissure, Body, Amazon (company), Most, Hemorrhoid, Heart, CMO, Online shopping, Cosmetics, Amazon, Bloop

PHILADELPHIA, Dec. 5, 2023 /PRNewswire-PRWeb/ -- Today marks a groundbreaking moment for Bloop as we announce the launch of our innovative colorectal care line on Amazon.com. This is not just another product launch; it's a game-changer for individuals seeking effective and natural solutions for conditions like hemorrhoids, fissures, and anal itch. Available now on Amazon are Bloop's Maximum Strength Hemorrhoid Relief Topical Cream, Itch Relief Cream, and Advanced Fissure Healing Cream.

Key Points: 
  • Available now on Amazon are Bloop's Maximum Strength Hemorrhoid Relief Topical Cream , Itch Relief Cream , and Advanced Fissure Healing Cream .
  • Launching our products on Amazon marks a significant step in making our unique colorectal care products more accessible to a wider audience.
  • Adrian Whant, CMO of Bloop, shares his enthusiasm: "Launching our products on Amazon marks a significant step in making our unique colorectal care products more accessible to a wider audience.
  • To discover Bloop products on Amazon, visit the store here .

Bloop Announces Launch of Three Products for Anorectal Care

Retrieved on: 
Monday, November 13, 2023
Dicarboxylic acid, Woman, Customs officer, Oil, Carapa, Seed, Pharmacist, Body, Most, Patient, Hemorrhoid, Heart, Pain, Anal, Skin, OTC, Cosmetics, Bloop, Copaifera

PHILADELPHIA, Nov. 13, 2023 /PRNewswire-PRWeb/ -- Bloop announced today the launch of their direct-to-consumer website, GotBloop.com. Bloop, a new personal care consumer health products company, is leading the way in offering treatment for the body's most sensitive areas.

Key Points: 
  • Bloop, a new personal care consumer health products company, is leading the way in offering treatment for the body's most sensitive areas.
  • Bloop is proud to stand as an ally to the LGBTQ+ community, committed to fostering inclusivity and understanding in colorectal care.
  • Bloop offers three separate formulations, each specifically targeting one of these ailments: anal fissures , anal itch , or hemorrhoids .
  • Bloop produces maximum strength innovative products with natural and active ingredients, making them the best alternative to traditional OTC anorectal products.

Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Monday, August 14, 2023
Transfer, FINANCIAL, Hemorrhoid, G&A, Research, Consultant, Sale, Accounting, Mazur, Patient, CRL, FDA, Safety, Cryptocurrency, Dietary supplement, Pharmaceutical industry, Security (finance), Life insurance, Citius, Altius, Fortius

CRANFORD, N.J., Aug. 14, 2023 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products today reported business and financial results for the fiscal third quarter ended June 30, 2023.

Key Points: 
  • $33.3 million in cash and cash equivalents as of June 30, 2023; runway through August 2024
    CRANFORD, N.J., Aug. 14, 2023 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products today reported business and financial results for the fiscal third quarter ended June 30, 2023.
  • THIRD QUARTER 2023 FINANCIAL RESULTS:
    As of June 30, 2023, the Company had $33.3 million in cash and cash equivalents.
  • For the fiscal quarter ended June 30, 2023, stock-based compensation expense was $1.2 million as compared to $1.0 million for the prior year period.
  • For the nine months ended June 30, 2023, stock-based compensation expense was $3.5 million as compared to $2.9 million for the nine months ended June 30, 2022.